AviadoBio
Aviadobio

     

AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London

by | May 15, 2025 | Press Releases

Press Release AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London • AVB-101 is an investigational one-time therapy designed to...

ABOUT US

Learn more about our mission to transform lives and our industry-leading team

About Us

Leadership Team

Board

Partners

SCIENCE & Innovation

Find out more about our innovative gene therapies

 

Science & Delivery

Pipeline

Delivery

Publications & Presentations

Programs

Our pipeline and programs reflect our mission to deliver the future of gene therapy

 

 

Programs

Pipeline

FTD 

Retinitis Pigmentosa

Alzheimer's and other Tauopathies

ALS

CAREERS

When you join AviadoBio, you join more than just a company, you join a dedicated team with a clear mission

 

Life at AviadoBio

Open Roles

CONTACT

We’d love to hear from you. If you have an enquiry about our gene therapies, delivery systems or clinical trials please contact us using the details here

For General Enquiries

For Patients and Caregivers

A Phase 1/2 open-label clinical study to evaluate the safety and preliminary efficacy of AVB-101 in people with a genetic sub-type of frontotemporal dementia (FTD-GRN) is now open for enrollment.

Clinical Trials5